NS Healthcare is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
Home » pressreleases » NATROX® O₂ Now Available Through NHS Supply Chain & NHS Shared Business Services

NATROX® Wound Care

Press
Release

NATROX® O₂ Now Available Through NHS Supply Chain & NHS Shared Business Services

Inotec AMD Ltd. is pleased to announce it has been recently added as an approved supplier to the UK’s NHS Supply Chain and NHS Shared Business Services (NHS SBS). Known for its innovative technology in advanced medical devices, Inotec is the maker of NATROX® Oxygen Wound Therapy. Its addition marks the first time continuous topical oxygen therapy (cTOT) has been listed. This new category means NHS staff, publicly funded organisations, hospitals, and wound care clinics can easily prescribe this highly effective therapy.

What is NATROX® Oxygen Wound Therapy

NATROX® Therapy is designed to heal chronic, hard-to-heal wounds. The innovative, simple device delivers pure humidified oxygen 24/7 directly to a wound to stimulate and improve healing. Battery-powered, portable, and completely silent, the active therapy is easy to maintain until a wound heals. It can be used during any phase of wound healing, works with any standard secondary dressing, and can even be used by patients remotely at home.

“We’re excited to become an approved NHS Supply Chain and NHS SBS supplier,” said Craig Kennedy, Inotec CEO. “But what’s even more exciting is the opportunity to transform the quality of life for so many patients who’ve potentially put their lives on hold just waiting to heal.”

The Burden of Chronic Wounds

Commonly understood as unhealed for at least three months1, chronic wounds pose a significant problem to both patients’ quality of life and healthcare systems worldwide2. Prevalent and costly, wound management accounts for healthcare expenditures of £8.3bn in the UK annually, of which 67% is spent managing unhealed, chronic wounds3.

“Knowing how high the stakes are and how many patients we can help is why I got involved,” said Dr. Adrian Parton MBE, Chairman of the Board at Inotec. The Cambridge-based firm focuses on groundbreaking innovation in advanced wound care technology. From award-winning products to its award-winning team, the young company has quickly captured the attention of many as a market leader in chronic wound healing.

Creating a New Category

Adding NATROX® Oxygen Wound Therapy to the NHS supplier frameworks marks the first time cTOT will be listed as a category. A mounting body of evidence demonstrates that topical oxygen therapy can improve both patient outcomes and quality of life5, 6, 7, 8.

“This move further validates NATROX® Therapy as an effective, needed treatment for patients across the UK suffering from hard-to-heal wounds,” said Parton. Making NATROX® Oxygen Wound Therapy widely available means improved wound healing, a higher likelihood of patient compliance, and a better quality of life.

“We believe NATROX® Therapy is poised to become the new standard in wound care,” said Parton.

Who are NHS Supply Chain and NHS SBS

NHS Supply Chain manages the sourcing, delivery and supply of healthcare products, services, and food for NHS trusts and healthcare organisations across England and Wales. NHS SBS delivers corporate services to the NHS, providing finance & accounting, procurement, and workforce services to more than half the NHS in England.

The goal of these providers is to help the NHS save money and enhance quality to allow the NHS to improve health, innovate to save lives, and deliver better outcomes with care and compassion.

“We work in partnership with suppliers focused on innovation whose products encourage good patient outcomes and support clinicians’ decision-making processes in both clinical and home care settings,” said Sue Mason, Senior Clinical Nurse Advisor at NHS SBS.

An estimated 85% of wound care costs9 relate to nursing and home visits rather than the wound dressing itself. With this in mind, the NHS SBS developed its Advanced Wound Care and Lymphoedema Products and Services Framework, under which NATROX® Oxygen Wound Therapyis listed, to help NHS nurses reduce time managing wounds.

“We help ensure clinicians can procure all their wound care needs via one route, enabling them to direct their time and resources back to patient care,” said Mason.

*How to Order

NATROX® Oxygen Wound Therapy can be ordered through standard procurement procedures. If using the NHS Supply Chain catalogue, find it by searching for keyword NATROX®. If ordering through NHS SBS, find NATROX® Oxygen Wound Therapy listed under Inotec AMD within the “Advanced Wound Care and Lymphoedema Therapies” category.

For queries about purchasing NATROX® Oxygen Wound Therapy in the UK, contact: nhs@natroxwoundcare.com.

About Inotec AMD, Ltd.
Inotec AMD Ltd is a specialist wound care company, based in Cambridge, England. Formed specifically to introduce new technologies to healthcare professionals around the world and promote faster and better healing to patients, the company is positioning NATROX® Oxygen Wound Therapy to be an integral part of global wound care treatment regimes in the coming years. To learn more, visit: natroxwoundcare.com.

For information about NHS Supply Chain, visit: www.supplychain.nhs.uk

For information about NHS Shared Business Services, visit: www.sbs.nhs.uk

REFERENCES

  1. Kyaw BM, Järbrink K, Martinengo L, et.al, 2018. Need for improved definition of “chronic wounds” in clinical studies. Acta Derm Venereol 2018;98:157–8.
  2. Gottrup, F. 2020. Portable, practical and effective: clinical benefits of NATROX® topical oxygen therapy. Journal of Wound Care May 2020, 29(5):53.
  3. Guest, JF, Fuller GW, Vowden P, 2020. Cohort study evaluating the buden of wounds to the UK’s National Health Service in 2017/18: update from 2012/13. BMJ Open 2020;10:e045253. doi:10.1136/ bmjopen-2020-045253.
  4. Gottrup, F. 2020. Portable, practical and effective: clinical benefits of NATROX® topical oxygen therapy. Journal of Wound Care May 2020, 29(5):53.
  5. Serena, T., 2020. Topical oxygen therapy has a role in wound care specialists’ armamentarium. iWoundsnews [online] 14 Dec 2020. Available at: https://bit.ly/iwounds2020 [Accesses 14 Oct 2021].
  6. Kauffman, H., et al, 2021. Topical oxygen therapy used to improve wound healing in a large retrospective study of wounds of mixed aetiology. Wounds International 2021, 12(2):62-68.
  7. Serena TE, Bullock NM, Cole W et al. Topical oxygen therapy in the treatment of diabetic foot ulcers: a multicentre, open, randomised controlled trial. J Wound Care 2021; 30: Suppl.5 S7-14.
  8. Dressings.Org.UK. Position statement 58: An SDMA response to the limitation of market access by NHS supply chain. [online] Available at: https://bit.ly/SDMA58 [Accessed 19 January 2022].
Contact NATROX® Wound Care

NATROX® Wound Care